|
Last Updated: Nov 18, 2006 - 12:32:53 PM |
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab effective in treating chronic graft-versus-host disease
A study by Dana-Farber Cancer Institute researchers offers the strongest evidence yet of the effectiveness of a novel therapy for chronic graft-versus-host disease (GVHD), a potentially life-threatening complication of donor bone marrow and stem cell transplants.
Mar 24, 2006 - 7:15:00 PM
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab maintenance therapy dramatically improves survival in lymphoma
Two years of maintenance therapy with MabThera (rituximab) dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkin�s Lymphoma (NHL). The trial showed that the risk of death is halved for patients who receive MabThera maintenance therapy, compared to those who receive no maintenance treatment, irrespective of their initial therapy. �We are conscious that these results open a new era in the management of indolent NHL�, said William M. Burns, CEO of the Pharmaceuticals Division at Roche. �Maintenance therapy with MabThera showed unprecedented survival benefits in a serious cancer disease which is currently considered incurable.�
Dec 13, 2005 - 3:36:00 PM
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab to be Considered for Front-Line Treatment of Intermediate Grade or Aggressive CD-20-positive, B-cell, non-Hodgkin's lymphoma
Genentech, Inc. , Biogen Idec, Inc. and Roche (SWX Zurich) today announced that the companies completed the filing of a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for an additional indication for Rituxan(R) (Rituximab), in previously untreated (front-line) patients with intermediate grade or aggressive, CD-20-positive, B-cell, non-Hodgkin's lymphoma (NHL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens.
Aug 18, 2005 - 11:45:00 AM
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
DANCER Study shows RA drug rituximab is safe and well-tolerated
In the biggest study of its kind, researchers have shown that the drug rituximab, used to treat rheumatoid arthritis (RA) is safe and effective. The results were presented for the first time today (Thursday 9 June), at the Annual European Congress of Rheumatology, EULAR 2005, in Vienna.
Jun 9, 2005 - 1:26:00 PM
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab may also benefit people with lupus
A drug used to treat cancer may also benefit people with lupus who have complications of the central nervous system. Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.
Jun 9, 2005 - 1:26:00 PM
<< prev
next >>
|
